Immune Design: Corporate Overview (Immune Design) - Aug 29, 2015 - Anticipated initiation of P2 trial in combination with atezolizumab for soft tissue sarcoma in Q4 2015; Anticipated data on dose escalation from P1 trial (NCT02387125) for solid tumors in YE 2015; Anticipated initial data from signal-seeking expansion arm of P1 trial (NCT02387125) for solid tumors in YE 2015
Anticipated new P2 trial • Anticipated P1 data • Oncology
|